FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE. SUITE 2400 AUSTIN. TEXAS 78701-2978 WWW.FULBRIGHT.COM

TKALE@FULBRIGHT.COM

TELEPHONE: FACSIMILE: (512) 474-5201 (512) 536-4598

July 21, 2008

Brandon J. Fetterolf, Examiner Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Our reference: INRP:095US

RE: U.S. Patent Application No. 10/043,877 Confirmation No.: 6285 Entitled "ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES" – Tapas Mukhopadhvay et al.

Dear Examiner Fetterolf:

Further to our letter of June 11, 2008 and the telephone conference between you and Dolly Milleson on July 17, 2008, I left a telephone message with you on Monday, July 21, 2008 regarding whether or not you had received and reviewed the copies of the references previously submitted with a Supplemental Information Disclosure Statement on July 30, 2003. We posted these references (references B4 (Canadian Application No. 2 343 470) and B5 (International Publication No. WO 02/076454)) to PAIR on July 17, 2008. I also wished to confirm your statement to Ms. Milleson that the drawings were properly corrected.

The payment of the issue fee is being made with the assumption that the SIDS references have been reviewed and accepted, and that the drawings have also been accepted. Please inform us if either assumption is incorrect.

We appreciate your assistance in this matter.

Sincerely,

Tamara A. Kale

TAK/tak